List Results
Refine Search
Results by Topic
Results on Map
Search Details
Found 11 studies with search of: triple negative breast cancer avastin
Hide studies that are not seeking new volunteers.
  Display Options
Rank Status Study
1 Active, not recruiting BEATRICE Study: A Study of Avastin (Bevacizumab) Adjuvant Therapy in Triple Negative Breast Cancer.
Condition: Breast Cancer
Interventions: Drug: bevacizumab [Avastin];   Drug: Standard adjuvant chemotherapy
2 Recruiting Weekly Paclitaxel/Carboplatin/Bevacizumab as First Line Therapy for Triple Negative Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: Bevacizumab;   Drug: Paclitaxel
3 Recruiting Phase II Study With Abraxane, Bevacizumab and Carboplatin in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Abraxane;   Drug: Bevacizumab;   Drug: Carboplatin
4 Recruiting Paclitaxel Albumin-Stabilized Nanoparticle Formulation and Bevacizumab Followed by Bevacizumab and Erlotinib in Treating Patients With Metastatic Breast Cancer
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: erlotinib hydrochloride;   Drug: paclitaxel albumin-stabilized nanoparticle formulation;   Other: laboratory biomarker analysis
5 Recruiting Paclitaxel With or Without Carboplatin and/or Bevacizumab Followed By Doxorubicin and Cyclophosphamide in Treating Patients With Breast Cancer That Can Be Removed by Surgery
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: carboplatin;   Drug: cyclophosphamide;   Drug: doxorubicin hydrochloride;   Drug: paclitaxel
6 Active, not recruiting Vorinostat, Paclitaxel, and Bevacizumab in Treating Patients With Metastatic Breast Cancer and/or Breast Cancer That Has Recurred in the Chest Wall and Cannot be Removed by Surgery
Condition: Breast Cancer
Interventions: Biological: bevacizumab;   Drug: paclitaxel;   Drug: vorinostat
7 Not yet recruiting Preoperative Chemotherapy in Triple Negative Invasive Breast Cancer That Can be Removed by Surgery.
Condition: Breast Cancer
Intervention: Drug: Bevacizumab, nab-paclitaxel, carboplatin, doxorubicin hydrochloride, cyclophosphamide, PEG-Filgrastim
8 Recruiting Phase II Trial of Doxil, Carboplatin, Bevacizumab in Triple Negative Untreated Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: Doxil;   Drug: Carboplatin;   Drug: Bevacizumab
9 Recruiting Bevacizumab and Abraxane as Second-Line Therapy in Triple Negative Metastatic Breast Cancer
Condition: Breast Cancer
Intervention: Drug: Bevacizumab, Abraxane
10 Recruiting Phase II Breast Cancer Treatment Using Weekly Carboplatin+Nab-paclitaxel, Plus Trastuzumab (HER2+) or Bevacizumab (HER2-)
Condition: Breast Cancer
Interventions: Drug: Carboplatin;   Drug: Nab-paclitaxel;   Drug: Trastuzumab (for HER2+);   Drug: Bevacizumab
11 Recruiting Capecitabine and Bevacizumab ± Vinorelbine in Metastatic Breast Cancer
Condition: Metastatic Breast Cancer
Interventions: Drug: capecitabine;   Drug: bevacizumab;   Drug: vinorelbine

Save this search by bookmarking this page.
When you use your bookmark, the search will be performed again on the most recent collection of studies.
RSS Feeds for studies found by your search that were:
  First received in the last 14 days,  
  Last updated (includes received) in the last 30 days
  Download Options




Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services